HealthEquity, Inc. (NASDAQ:HQY - Get Free Report)'s share price gapped down before the market opened on Wednesday . The stock had previously closed at $101.67, but opened at $85.00. HealthEquity shares last traded at $82.74, with a volume of 1,085,175 shares.
Analysts Set New Price Targets
Several brokerages recently commented on HQY. Royal Bank of Canada raised their price objective on HealthEquity from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 10th. Wells Fargo & Company raised their price objective on HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Barrington Research reissued an "outperform" rating and issued a $112.00 price target on shares of HealthEquity in a research note on Friday, March 14th. JMP Securities lifted their price target on HealthEquity from $105.00 to $107.00 and gave the company a "market outperform" rating in a research note on Tuesday, December 10th. Finally, Raymond James lifted their price target on HealthEquity from $105.00 to $120.00 and gave the company an "outperform" rating in a research note on Tuesday, February 25th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $112.92.
Read Our Latest Research Report on HQY
HealthEquity Trading Up 0.3 %
The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The business has a 50-day moving average of $104.90 and a 200-day moving average of $95.76. The firm has a market cap of $7.36 billion, a price-to-earnings ratio of 77.87, a P/E/G ratio of 1.60 and a beta of 0.62.
Insider Activity at HealthEquity
In related news, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $111.29, for a total value of $639,917.50. Following the sale, the director now owns 78,219 shares of the company's stock, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.20% of the stock is owned by company insiders.
Institutional Trading of HealthEquity
Hedge funds and other institutional investors have recently modified their holdings of the stock. Holocene Advisors LP bought a new position in HealthEquity during the third quarter worth about $1,246,000. Loomis Sayles & Co. L P grew its holdings in HealthEquity by 2.2% during the third quarter. Loomis Sayles & Co. L P now owns 1,126,645 shares of the company's stock worth $92,216,000 after purchasing an additional 24,665 shares during the period. HighTower Advisors LLC grew its holdings in HealthEquity by 4.8% during the fourth quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock worth $9,122,000 after purchasing an additional 4,370 shares during the period. Geneva Capital Management LLC grew its holdings in HealthEquity by 24.6% during the fourth quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company's stock worth $100,642,000 after purchasing an additional 206,894 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in HealthEquity by 165.7% during the third quarter. BNP Paribas Financial Markets now owns 20,437 shares of the company's stock worth $1,673,000 after purchasing an additional 12,745 shares during the period. Institutional investors and hedge funds own 99.55% of the company's stock.
About HealthEquity
(
Get Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.